Gh Research Plc (GHRS)

$11.19

+0.19

(+1.73%)

Market is closed - opens 7 PM, 15 Apr 2024

Insights on Gh Research Plc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 47.7% return, outperforming this stock by 8.9%

Performance

  • $10.96
    $11.19
    $11.19
    downward going graph

    2.06%

    Downside

    Day's Volatility :2.06%

    Upside

    0.0%

    downward going graph
  • $5.05
    $14.64
    $11.19
    downward going graph

    54.87%

    Downside

    52 Weeks Volatility :65.51%

    Upside

    23.57%

    downward going graph

Returns

PeriodGh Research PlcSector (Health Care)Index (Russel 2000)
3 Months
91.28%
-1.1%
0.0%
6 Months
39.18%
6.7%
0.0%
1 Year
34.17%
3.2%
-0.7%
3 Years
-42.75%
15.2%
-21.6%

Highlights

Market Capitalization
572.3M
Book Value
$4.21
Earnings Per Share (EPS)
-0.68
Wall Street Target Price
31.75
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-10.72%
Return On Equity TTM
-15.18%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-41.2M
Diluted Eps TTM
-0.68
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.94
EPS Estimate Next Year
-1.26
EPS Estimate Current Quarter
-0.2
EPS Estimate Next Quarter
-0.2

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Gh Research Plc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 183.74%

Current $11.19
Target $31.75

Technicals Summary

Sell

Neutral

Buy

Gh Research Plc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Gh Research Plc
Gh Research Plc
2.66%
39.18%
34.17%
-42.75%
-42.75%
Moderna, Inc.
Moderna, Inc.
1.24%
14.36%
-26.97%
-34.23%
306.89%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.2%
7.24%
10.36%
82.9%
140.93%
Novo Nordisk A/s
Novo Nordisk A/s
-5.94%
23.09%
45.57%
248.23%
394.48%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.73%
6.03%
21.0%
79.35%
117.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Gh Research Plc
Gh Research Plc
NA
NA
NA
-0.94
-0.15
-0.11
NA
4.21
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.2
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.28
26.28
1.51
44.87
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.38
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.64
28.64
0.54
16.78
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Gh Research Plc
Gh Research Plc
Buy
$572.3M
-42.75%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.0B
306.89%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$100.2B
140.93%
26.28
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$565.1B
394.48%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$102.8B
117.3%
28.64
36.68%

Institutional Holdings

  • Checkpoint Capital LP

    0.56%

Corporate Announcements

  • Gh Research Plc Earnings

    Gh Research Plc’s price-to-earnings ratio stands at None

    Read More

Company Information

gh research is a privately-held clinical-stage biopharmaceutical company developing novel therapies for the management of mental illness.

Organization
Gh Research Plc
Employees
49
CEO
Mr. Florian Schonharting M.Sc. (Econ)
Industry
Healthcare

FAQs